NCT01227512终止3 期
Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia
Otsuka Pharmaceutical Development & Commercialization, Inc.2 个研究点 分布在 1 个国家目标入组 124 人开始时间: 2010年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 124
- 试验地点
- 2
- 主要终点
- Length of Hospital Stay (LoS)
研究概览
简要总结
The purpose of this study is to determine if hospitalized patients with symptomatic hyponatremia treated with tolvaptan are in the hospital for less time than patients treated with fluid restriction. The study will also test if tolvaptan is better than fluid restriction in treating the symptoms of hyponatremia in hospitalized patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Hyponatremia in clinically euvolemic or hypervolemic states, defined as serum sodium < 130 mEq/L prior to randomization
- •Clinically significant symptoms of hyponatremia, defined as a CGI-S score between 3-6, inclusive
- •Female subjects of child bearing potential who agree to remain abstinent or to practice double-barrier forms of birth control from screening through 30 days following first dose on IMP
排除标准
- •Women who are pregnant or breast feeding, and females of childbearing potential who are not using acceptable contraceptive methods (such as barrier contraceptives or methods that result in a failure rate of less than 1%)
- •Hyponatremia in hypovolemic states, defined as the presence of clinical and historical evidence of extracellular fluid volume depletion, including but not limited to skin turgor, orthostatic changes in blood pressure or heart rate, dry mucous membranes, or a response to IV saline challenge
- •Subjects who are likely to require prolonged hospitalization for reasons other than hyponatremia, eg. new femoral fracture, surgeries requiring extended recovery
- •Recent prior treatment for hyponatremia: hypertonic saline (including normal saline challenge) (within 8 hours of baseline) or urea, lithium, demeclocycline, conivaptan or tolvaptan (within 4 days of baseline). Includes any treatment, other than fluid restriction for the purpose of increasing serum sodium.
- •Hyponatremia symptoms of a severity (eg, CGI = 7) such that they require immediate intervention with hypertonic saline; or are expected to require such therapy within 48 hours
- •Causes of neurological symptoms which are attributable to psychological (psychosis), structural (dementia of the Alzheimer's type, stroke, transient ischemic attack, multi-infarct dementia) or other metabolic causes (eg. hyper- or hypo-: oxemia, glycemia, calcemia, ammonemia, etc)
- •Acute and transient hyponatremia associated with head trauma or severe neurological injury (eg. stroke, subdural hematoma)or the use of recreational drugs.
- •History of hyponatremia known to be due to severe, untreated hypothyroidism/adrenal insufficiency
- •Subjects with psychogenic polydipsia
- •Systolic arterial blood pressure < 90 mmHg at screening
- •History of hypersensitivity and/or idiosyncratic reaction to benzazepine or benzazepine derivatives (such as benazepril), or tolvaptan
- •History of drug or medication abuse within the 3 months prior to screening, or current alcohol abuse
- •Uncontrolled diabetes mellitus defined as glucose > 300 mg/dL [16.7 mmol/L]
- •Current urinary tract obstruction (eg, obstructive benign prostatic hypertrophy)
- •Current condition of anuria
- •Serum creatinine > 3.5 mg/dL at screening
- •Terminally ill or moribund condition with little chance of short-term (eg, 30 day) survival
- •Subjects whose hyponatremia is the result of any medication that can safely be withdrawn (examples of drugs often not withdrawn include: anticonvulsants [eg, carbamazepine] and antipsychotics [eg, haloperidol])
- •Patients receiving DDAVP within 2 days of screening
- •Patients with history of active variceal bleeding within the past 30 days, without prior approval from sponsor medical monitor
- •Participation in another investigational drug trial within the past 30 days
研究组 & 干预措施
Tolvaptan 15-60mg
Experimental
Oral tablet without fluid restriction. After the initial dose, daily dose may be titrated based on response.
干预措施: tolvaptan (Drug)
Fluid Restriction
Active Comparator
Placebo tablet with prescribed fluid restriction. After the initial dose, level of fluid restriction may titrated based response.
干预措施: Fluid Restriction (Other)
结局指标
主要结局
Length of Hospital Stay (LoS)
时间窗: 45 days
LoS was time to clinically ready to be hospital discharged (CRBD) from study treatment initiation, disregarding prolonged hospitalization due solely to social factors.
次要结局
- Change From Baseline to 48 Hour Post Dose in Clinical Global Impression-Severity (CGI-S) of Hyponatremia Symptoms.(Baseline to 48 hours post dose)
- Change From Baseline to 24 and 72 Hours Post Dose in CGI-S of Hyponatremia Symptoms.(Baseline to 24 and 72 hours post dose)
- Change From Baseline to 48 Hours Post Dose in Clinical Global Impression - Improvement (CGI-I) Score of Hyponatremia Symptoms.(Baseline to 48 hours post dose)
- Change From Baseline in Serum Sodium Concentration (24 Hour Area Under the Curve [AUC]).(0 to 72 hours)
- Time to First 2-point Improvement in CGI-S Score.(Up to 72 hours)
- Percentage of Participants With Clinical Global Impression-Improvement (CGI-I) Score Improved to a Score of 1 or 2.(48 hours post dose)
- Percentage of Participants Requiring Rescue Therapy for Hyponatremia(7 days)
研究者
研究点 (2)
Loading locations...
相似试验
终止
2 期
Tolvaptan for In-hospital HyponatremiaHyponatremiaNCT01386372Mario Negri Institute for Pharmacological Research3
Unknown
不适用
The Clinical and Laboratory Characteristics of Recurrent Drug- Related HyponatremiaSIADHHyponatremiaNCT01509170Hadassah Medical Organization500
撤回
不适用
Fractional Urate Excretion in Nonedematous HyponatremiaCerebral HyponatremiaSIADHCerebral Salt-wasting SyndromeReset Hypothalamic OsmostatNCT01425125NYU Langone Health
尚未招募
4 期
A Prospective study of Hyponatremia in lower respiratory childreCTRI/2018/12/016534Goverment Medical college bhavnagar
已完成
不适用
Evaluation of postoperative hyponatremia in patients admitted in urology ward with two different intravenous fluids.Hyponatremia.Hypo-osmolality and hyponatraemiaIRCT2014122720448N1Tehran University of Medical Sciences150